Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares of Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $35.12, for a total transaction of $649,720.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $8,261,769.28. This represents a 7.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00.
• On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $37.93, for a total transaction of $701,705.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA traded up $0.90 during trading hours on Friday, hitting $35.89. The stock had a trading volume of 1,184,368 shares, compared to its average volume of 1,505,769. The stock’s fifty day simple moving average is $35.99 and its 200 day simple moving average is $37.47. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -6.12 and a beta of 0.96. Vera Therapeutics, Inc. has a 1-year low of $21.96 and a 1-year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period last year, the firm earned ($1.20) earnings per share. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -6.45 earnings per share for the current fiscal year.

Institutional Trading of Vera Therapeutics

A number of large investors have recently bought and sold shares of VERA. Los Angeles Capital Management LLC bought a new position in shares of Vera Therapeutics during the fourth quarter valued at $46,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics during the 4th quarter valued at about $71,000. Quantbot Technologies LP bought a new stake in Vera Therapeutics during the second quarter worth about $51,000. Nykredit A S bought a new position in shares of Vera Therapeutics in the second quarter valued at approximately $97,000. Finally, Sandia Investment Management LP bought a new stake in Vera Therapeutics during the 4th quarter worth approximately $127,000. 99.21% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on VERA. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Guggenheim raised their price target on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $84.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, August 11th. Bank of America lifted their target price on Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $34.00 price target on shares of Vera Therapeutics in a report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $81.15.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.